Incanthera Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • INC

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.07
  • (As of Wednesday Closing)

Incanthera General Information

Description

Incanthera PLC is a UK-based dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. It has developed sophisticated formulation and targeting technology platforms to address options across dermatology and oncology. These deliver treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy. The company is currently focusing on its Skin + CELL luxury skincare range, which includes products that help protect mitochondria to keep cells energetic and healthy, giving skin the ability to protect, repair, and thrive. Additionally, it continues to develop and expand on its dermatology formulation and delivery expertise for many further areas of identified opportunity.

Contact Information

Formerly Known As
Incanthera Ltd
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 98 King Street
  • C/O Gateley Legal, Ship Canal House
  • Manchester M2 4WU
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
AQSE
Vertical(s)
Corporate Office
  • 98 King Street
  • C/O Gateley Legal, Ship Canal House
  • Manchester M2 4WU
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Incanthera Stock Performance

As of 18-Nov-2026, Incanthera’s stock price is $0.07. Its current market cap is $9.1M with 138M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.07 $0.07 $9.1M 138M 351K -$0.02

Incanthera Financials Summary

As of 31-Mar-2026, Incanthera has a trailing 12-month revenue of $16.1K.

In Thousands,
USD
TTM 31-Mar-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 2,442 2,442 14,888 14,979
Revenue 16 16 0 0
EBITDA (3,046) (3,046) (2,473) (1,851)
Net Income (2,905) (2,905) (2,547) (1,944)
Total Assets 1,361 1,361 2,199 210
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Incanthera Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Incanthera‘s full profile, request access.

Request a free trial

Incanthera Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Incanthera‘s full profile, request access.

Request a free trial

Incanthera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Incanthera PLC is a UK-based dermatology and oncology therapeutics company focusing on discovery and development of targ
Drug Discovery
Manchester, United Kingdom
8 As of 2026

Hellerup, Denmark
 

Oban, United Kingdom
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Incanthera Competitors (6)

One of Incanthera’s 6 competitors is Union Therapeutics, a Venture Capital-Backed company based in Hellerup, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Union Therapeutics Venture Capital-Backed Hellerup, Denmark
Aquapharm Biodiscovery Formerly VC-backed Oban, United Kingdom
Dermavant Sciences Formerly PE-Backed Long Beach, CA
Verrica Pharmaceuticals Formerly VC-backed West Chester, PA
Arcutis Biotherapeutics Formerly VC-backed Westlake Village, CA
To view Incanthera’s complete competitors history, request access »

Incanthera Patents

Incanthera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202106934-D0 Topical formulation Inactive 14-May-2021
AU-2021318827-A1 Topical formulation Pending 27-Jul-2020
CA-3186807-A1 Topical formulation Pending 27-Jul-2020
EP-4188325-A1 Topical formulation Pending 27-Jul-2020
GB-202011605-D0 Topical formulation Inactive 27-Jul-2020
To view Incanthera’s complete patent history, request access »

Incanthera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Incanthera Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Incanthera‘s full profile, request access.

Request a free trial

Incanthera Acquisitions (3)

Incanthera’s most recent deal was a Merger/Acquisition with Enielle. The deal was made on 04-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Enielle 04-Jun-2026 Merger/Acquisition Personal Products
Incanthera Therapeutics 28-Jan-2015 Merger/Acquisition Drug Discovery
Onco-NX 11-Mar-2014 Merger/Acquisition Drug Discovery
To view Incanthera’s complete acquisitions history, request access »

Incanthera ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Incanthera’s complete esg history, request access »

Incanthera Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Onco-NX Manchester, United Kingdom 2011
Incanthera Therapeutics Manchester, United Kingdom 2002

Incanthera FAQs

  • When was Incanthera founded?

    Incanthera was founded in 2010.

  • Where is Incanthera headquartered?

    Incanthera is headquartered in Manchester, United Kingdom.

  • What is the size of Incanthera?

    Incanthera has 8 total employees.

  • What industry is Incanthera in?

    Incanthera’s primary industry is Drug Discovery.

  • Is Incanthera a private or public company?

    Incanthera is a Public company.

  • What is Incanthera’s stock symbol?

    The ticker symbol for Incanthera is INC.

  • What is the current stock price of Incanthera?

    As of 18-Nov-2026 the stock price of Incanthera is $0.07.

  • What is the current market cap of Incanthera?

    The current market capitalization of Incanthera is $9.1M.

  • What is Incanthera’s current revenue?

    The trailing twelve month revenue for Incanthera is $16.1K.

  • Who are Incanthera’s competitors?

    Union Therapeutics, Aquapharm Biodiscovery, Dermavant Sciences, Verrica Pharmaceuticals, and Arcutis Biotherapeutics are some of the 6 competitors of Incanthera.

  • What is Incanthera’s annual earnings per share (EPS)?

    Incanthera’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process